However, due to the ease of intravenous administration in individuals under hemodialysis, lack of pain or stinging sensation, and also the risk of rare but serious complication of pure red cell aplasia that occurs more frequently in subcutaneous administration of EPO, intravenous injection appears to be a better option than subcutaneous injection in hemodialysis patients [13]. Here, EPO is linked to Pure red cell aplasia.